Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary V Relling

Showing results (101-110 of 295) with videos related to

Pageof 30
Sort By:
Pharmacogenomics|December 15, 2016
The impact of the UGT1A1*60 allele on bilirubin serum concentrationsAmy L Pasternak, Kristine R Crews, Kelly E Caudle, et al.
Blood|August 5, 2020
Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatmentYiwei Liu, John C Panetta, Wenjian Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemiaMary V Relling, Wenjian Yang, Soma Das, et al.
Pediatric Blood & Cancer|February 14, 2019
Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosisEmily R Finch, Laura J Janke, Colton A Smith, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2021
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginaseJohn C Panetta, Yiwei Liu, Teodoro Bottiglieri, et al.
Blood|December 15, 2010
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemiaJitesh D Kawedia, Sue C Kaste, Deqing Pei, et al.
Blood|January 18, 2003
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatmentMary V Relling, James M Boyett, Javier G Blanco, et al.
Annual Review of Pharmacology and Toxicology|October 9, 2014
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centersHenry M Dunnenberger, Kristine R Crews, James M Hoffman, et al.
Clinical Pharmacology and Therapeutics|November 9, 2018
Essential Characteristics of Pharmacogenomics Study PublicationsCaroline F Thorn, Michelle Whirl-Carrillo, Houda Hachad, et al.
Pediatric Blood & Cancer|February 15, 2011
Neuropathic pain during treatment for childhood acute lymphoblastic leukemiaDoralina L Anghelescu, Lane G Faughnan, Sima Jeha, et al.
Pageof 30

Showing results (101-110 of 295) with videos related to

Sort By:
Pageof 30
Pharmacogenomics|December 15, 2016
The impact of the UGT1A1*60 allele on bilirubin serum concentrationsAmy L Pasternak, Kristine R Crews, Kelly E Caudle, et al.
Blood|August 5, 2020
Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatmentYiwei Liu, John C Panetta, Wenjian Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemiaMary V Relling, Wenjian Yang, Soma Das, et al.
Pediatric Blood & Cancer|February 14, 2019
Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosisEmily R Finch, Laura J Janke, Colton A Smith, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2021
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginaseJohn C Panetta, Yiwei Liu, Teodoro Bottiglieri, et al.
Blood|December 15, 2010
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemiaJitesh D Kawedia, Sue C Kaste, Deqing Pei, et al.
Blood|January 18, 2003
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatmentMary V Relling, James M Boyett, Javier G Blanco, et al.
Annual Review of Pharmacology and Toxicology|October 9, 2014
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centersHenry M Dunnenberger, Kristine R Crews, James M Hoffman, et al.
Clinical Pharmacology and Therapeutics|November 9, 2018
Essential Characteristics of Pharmacogenomics Study PublicationsCaroline F Thorn, Michelle Whirl-Carrillo, Houda Hachad, et al.
Pediatric Blood & Cancer|February 15, 2011
Neuropathic pain during treatment for childhood acute lymphoblastic leukemiaDoralina L Anghelescu, Lane G Faughnan, Sima Jeha, et al.
Pageof 30